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Abstract
Background: Because some of heat shock protein 90's (HSP90) clients are key cell cycle regulators, HSP90 inhibition 
can affect the cell cycle. Recently, celastrol is identified both as a novel inhibitor of HSP90 and as a potential anti-tumor 
agent. However, this agent's effects on the cell cycle are rarely investigated. In this study, we observed the effects of 
celastrol on the human monocytic leukemia cell line U937 cell cycle.
Results: Celastrol affected the proliferation of U937 in a dose-dependent way, arresting the cell cycle at G0/G1 with 
400 nM doses and triggering cell death with doses above 1000 nM. Cell cycle arrest was accompanied by inhibition of 
HSP90 ATPase activity and elevation in HSP70 levels (a biochemical hallmark of HSP90 inhibition), a reduction in Cyclin 
D1, Cdk4 and Cdk6 levels, and a disruption of the HSP90/Cdc37/Cdk4 complex. The observed effects of celastrol on the 
U937 cell cycle were thiol-related, firstly because the effects could be countered by pre-loading thiol-containing 
agents and secondly because celastrol and thiol-containing agents could react with each other to form new 
compounds.
Conclusions: Our results disclose a novel action of celastrol-- causing cell cycle arrest at G0/G1 phase based upon 
thiol-related HSP90 inhibition. Our work suggests celastrol's potential in tumor and monocyte-related disease 
management.
Background
Cancer therapy targeting HSP90 has shown great prom-
ise [1,2]. A wide range of oncogenic client proteins crucial
for oncogenesis are stabilized, matured by, and thus
dependent on HSP90. The harsh environmental condi-
tions found in tumors, such as hypoxia and low pH, as
well as outside factors, such as poor nutrition, tend to
destabilize proteins and further their dependence on
HSP90. This hypothesis is supported by the higher
HSP90 levels found in tumor cells, which can comprise as
much as 4-6% of cellular proteins in contrast to the 1-2%
seen in normal cells [3,4]. When used as a single agent or
in combination with chemotherapy, HSP90 inhibitors
have shown anti-tumor effects in cellular studies, animal
model studies, and clinical evaluations [5-7]. However, it
is too early for many of these inhibitors or their deriva-
tives to have received Food and Drug Administration
approval. In this sense, research on novel HSP90 inhibi-
tors is attractive.
Natural substances are often key components of HSP90
inhibitors [8]. After geldanamycin, a natural product iso-
lated from the bacteria Streptomyces hygroscopicus, was
f o u n d  t o  b e  a n  H S P 9 0  i n h i b i t o r ,  a  v a r i e t y  o f  n a t u r a l
HSP90 inhibitors have been identified. Among these are
herbimycin, radicicol, novobiocin, coumermycin A1, clo-
robiocin, epigallocatechin gallate, taxol, pochonin, derru-
bone, gedunin, and the more recently identified celastrol
[2]. Celastrol, also called tripterine, is a quinone methide
triterpenoid isolated from the Chinese plant Triptery-
gium wilfordii Hook F (TWHF), which has been used as
an anti-rheumatic in China for many years. Celastrol can
activate HSF1, induce expression of some HSPs [9,10],
down-regulate HSP90's ability in binding to ATP [11],
and disrupt the combination of HSP90 with co-chaper-
one Cdc37 [12]. All these effects indicate inhibition of
HSP90 activities. In agreement with data on the anti-
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tumor effects of other HSP90 inhibitors, celastrol showed
similar action upon a variety of tumor cells [11-15].
Moreover, using in silico screens of public gene expres-
sion data, celastrol has recently been discovered to eradi-
cate acute myelogenous leukemia stem cells through
simultaneous inhibition of NF-κ B-mediated survival sig-
nals and induction of oxidative stress [16]. It is therefore
possible that when compared to other HSP90 inhibitors
celastrol possesses unique anti-tumor properties.
Anti-tumor effects can be achieved by cell death and/or
cell cycle arrest. Until now, most reports attributed celas-
trol's anti-tumor effects on its death-triggering action,
leaving celastrol's effects on cell cycle almost unexplored.
Some key cell cycle regulator proteins, such as Cdk4 and
Cdk6, are clients of HSP90 (see the website http://
www.picard.ch for further details), and the partner/acti-
vator of these Cdks, Cyclin D1, is also affected by the
HSP90 molecular chaperone. It has been proven that
HSP90 inhibitors can affect these Cdks and Cyclin D1,
causing cell cycle arrest [17,18]. As a novel inhibitor of
HSP90, celastrol might also affect these proteins and
cause cell cycle arrest, an issue that needs to be ade-
quately addressed to fully understand celastrol's anti-
tumor effects.
In this study, we observed the effects of celastrol on
proliferation in human monocytic leukemia cell line
U937. The results showed that in addition to quickly
inducing apoptosis at high doses, celastrol could also
arrest cells at G0/G1 phase at lower dosages. These
effects were accompanied by elevation of HSP70 levels,
down-regulation of Cyclin D1 and Cdk4, and a reduction
in HSP90/Cdc37/Cdk4 complex levels. All of these
actions could be reversed by pre-treatment of cells with
small thiol-containing molecules, whereas non-thiol anti-
oxidant agents could not reverse celastrol's effects.
Chemical reaction confirmed celastrol's interaction with
the thiol group. Our study discloses celastrol's novel
action on the cell cycle and sheds additional light on the
working mechanisms of this agent.
Results
Antiproliferative effects of celastrol
U937 cellular numbers were determined by FCM based
on a modified one-tube platform, which can accurately
count the number of total, living, and dead cells in a sam-
ple [19,20]. After being cultured for 1 day in vitro,
untreated U937 demonstrated rapid proliferation, with
cellular numbers about 2.4 times the initial quantity. As
shown in Figure 1A, when the final dosage of celastrol
used reached 400 nM, U937 numbers began decreasing
compared to the untreated control; as dosages increased
further, cell numbers gradually decreased. At 1600 nM,
U937 quantities were almost the same as the original
numbers.
Further analysis disclosed two ways in which celastrol
reduced cell numbers. At dosages ranging from 400 nM
to 800 nM, the total number of cells (living and dead)
decreased, but dead cell numbers remained constant.
Therefore, within this range, cell division disruption was
the main reason for cell number reductions. With doses
of 800 nM and higher, dead cells increased with dose
increases (Figure 1A). This implies an additional cause of
proliferation inhibition - i.e.: celastrol began to cause cell
death. In fact, a dose-driven rise in apoptotic rates at
doses above 1000 nM was revealed by flow cytometric
(FCM) analysis of Annexin V/PI stained cells (Figure 1B
and 1C).
Cell cycle arrested at G0/G1 by celastrol
Cell cycle was determined by FCM based on PI staining
of DNA contents. U937 cells demonstrated a normal dip-
loid distribution in the untreated control, showing fast
proliferation characteristics; with cells in S + G2/M
accounting for more than half of the cell total. Celastrol at
400 nM reduced cellular numbers as mentioned above
and caused a correspondent increase in the number of
cells at G0/G1, a change that continued until dosage
reached 800 nM (Figure 2). The maximum dose used in
this study was 800 nM, as samples treated with doses
above 800 nM had large dead cell populations that inter-
fered with accurate calculation of cell cycle location.
Reducing the levels of Cyclin D1, Cdk2, Cdk4, and Cdk6 in 
U937
Cyclin D1 and some Cdks are important to cell cycle
progress at G1 phase. To examine whether the observed
G0/G1 arrest was related to changes in these proteins, we
tested some of them by FCM. The results showed that all
cells, treated or not, were positive for Cyclin D1, Cdk4,
Cdk6, and Cdk2. FCM detection showed that Cyclin D1
was down-regulated by celastrol in a dose-dependent way
(Figure 3A). Antibody labelling of Cyclin D1 in conjunc-
tion with 7-AAD staining of DNA content was performed
to determine the relationship between Cyclin D1 reduc-
tion and different cell cycle phases. The results showed
that the reduction of this protein was not related to the
cells' location in cycle, as the cells at G0/G1, S, and G2/M
phases all displayed similar degrees of Cyclin D1 expres-
sion decrease (data not shown).
Of the three Cdks detected, Cdk4 was reduced most
greatly, while Cdk2 and Cdk6 levels were less affected by
celastrol (Figure 3B). It has been reported that Cdk4 is
more sensitive to HSP90 inhibitors than Cdk2 and Cdk6
[17]. Since Cdk4 acts during the early G1 stage, while
Cdk6 and Cdk2 acting sequentially later, celastrol-caused
arrest likely begins at the onset of G1. As was the case
with Cyclin D1, the reductions of Cdk4, Cdk6, and Cdk2Peng et al. Molecular Cancer 2010, 9:79
http://www.molecular-cancer.com/content/9/1/79
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Figure 1 Effects of celastrol on U937 culture proliferation and viability in vitro. Cells were seeded at 2 × 105/ml in 96-well culture plate and treat-
ed with indicated doses of celastrol for 1 d. A: Dose-dependent effects of celastrol on the number of total, living and dead cells. After treatment, the 
numbers of living and dead cells in each sample was determined by single-tube platform flow cytometry using self-made cell-Beads as an internal 
standard (detailed in Methods). Each data point represents the mean value of three test repetitions. B: Dot plot for flow cytometric analysis of living 
and apoptotic cells. The samples were labeled with Annexin V- FITC and PI double staining, and then detected by FCM. Living cells tested negative 
for both Annexin V and PI. Populations testing Annexin V positive/PI negative were in early-stage apoptosis, and double positives were in late-stage 
apoptosis. The percentages of each population are labeled in the corresponding plot region. C. Bar graph showing percentage of living, early, and 
late-stage apoptotic cells in samples with varying treatments. The values shown are the mean of three independent experiments.
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Figure 2 Celastrol arrests cell cycle at G0/G1 phase in U937. Following the treatment, cells were incubated with RNase A and PI, cell cycle was 
assayed by FCM. A: Panel of flow cytometric histograms showing DNA content in samples treated with various doses of celastrol. X-axis represents 
DNA content and Y-axis shows cell number. B: Percentages of sample cells in each cell cycle phase. The dose-effects of celastrol on the percentages 
of U937 cells at each phase of cell cycle are shown. Each value is found as the mean of three independent experiments.
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Figure 3 Celastrol decreases the level of Cyclin D1 and some Cdks. Following treatment, cells were incubated with indicated antibodies and the 
expressions of proteins were detected by FCM detailed in Methods. A: Celastrol induces reduction of Cyclin D1 in a dose-dependent manner. The left 
panel shows the histogram for FCM detection of Cyclin D1 expression with X-axis as fluorescence intensity and Y-axis representing cell number. The 
right panel shows the detected intensities of this protein. Each value represents the mean of three independent experiments. B: Effects of celastrol on 
Cdk4, Cdk6, and Cdk2 expressions. After exposure to 600 nM celastrol for 1 d, the proteins were detected by FCM. Y-axis represents the relative levels 
of each protein in different treatments, with the protein level in DMSO-control sample being set at 1.0. Each value is the mean of three independent 
experiments.
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levels were unrelated to the cells' location in cycle (data
not shown).
Elevation of HSP70, inhibition of HSP90's ATPase activity, 
and disruption of the HSP90/Cdc37/Cdk4 Complex in U937 
by Celastrol
Since celastrol is reported to inhibit HSP90 activity in
several cellular models [11,12,21], and Cdk4 and Cdk6 are
clients of HSP90, we hypothesized Cdks reduction in our
model might be related to HSP90 activity. To test this
hypothesis, we first detected celastrol's effect on HSP90
activity and then determined HSP90/Cdc37/Cdk4's lev-
els.
A regenerating coupled enzyme assay [22] was used to
observe celastrol's effects on ATPase activity in the pro-
tein complex pulled-down by anti-HSP90. We found that
the ATPase activity in this HSP90-containing complex
was inhibited by celastrol (Figure 4A) (Inhibition of
ATPase activity in the HSP90 complex was also con-
firmed by a different ATPase assay method, see additional
file 1). Additionally, as shown in Figure 4B, expression of
HSP70 elevated nearly 4.5 fold when 600 nM of celastrol
was used. Since induction of HSP70 is indicative of
HSP90 inhibition, we believe that celastrol exerted
HSP90-inhibiting activity in our model.
Then we observed celastrol's effects on HSP90/Cdc37/
Cdk4 complex. As seen in Figure 4C, the protein complex
immunoprecipitated by the anti-HSP90 antibody showed
lower levels of Cdk4 and Cdk6, indicating that HSP90/
Cdc37/Cdk4 complex formation was disrupted by celas-
trol. The results showed that the Cdc37 co-chaperone
levels in the complex were also decreased, this result is
consistent with the previous report that celastrol dis-
rupted Cdc37-HSP90 interaction [12].
Free thiol-containing agents prevented the effects of 
celastrol
Other models have reported that thiol can reverse the
action of celastrol [9], so we tested thiol in our model.
The results showed that pre-treatment with the thiol-
containing agent N-acetylcysteine (NAC) 1 h before load-
ing celastrol could effectively reverse celastrol's cell cycle
arresting action. However, the non-thiol reducing agent
we tested, vitamin C (Vit C), did not work in this way.
Other thiol-containing agents, such as reduced glutathi-
one (GSH), also showed reversing effects, while oxidized
glutathione (GSSG), an agent containing sulfur but with-
out free thiol, did not exhibit countering effects (Figure
5B). Accordingly, elevated levels of HSP70 and down-reg-
ulation of Cdks, Cyclin D1, and Cdc37 by celastrol were
reversed by NAC but not by Vit C (Figure 5A and 5C).
Free thiol-containing amino acid synthesis with celastrol 
via chemical reaction
To find out the reason for free thiol-containing agents'
reversing effect, we tested if celastrol could directly react
with thiol. When celastrol was mixed with the thiol-con-
taining agents, NAC, GSH, or Dithiothreitol (DTT), cel-
astrol's colour disappeared. This colour change was not
seen when celastrol was mixed with Vit C or GSSG.
When excited by UV light, celastrol showed an absor-
bance peak at 440 nm which disappeared when incubated
with free thiol-containing agents (NAC, GSH or DTT).
The absorbance peak was unaffected when incubated
with GSSG or non-thiol reducing agent Vit C (Figure 6A).
To further confirm a celastrol-thiol reaction, we per-
formed mass spectrum (MS) analysis on the addition
compounds formed by celastrol and thiol- (non thiol-)
containing agents. The observed m/z 473.18 in the sam-
ple of celastrol alone in DMSO was consistent with predi-
cation of celastrol (MW 450) plus one natrium ion
(Figure 6B). The calculated mass of celastrol plus DTT
and one natrium agreed well with the observed m/z
627.25, indicating that these two molecules reacted and
produced a new compound with a larger mass (Figure 6C,
see additional file 2 for non-truncated view). Similar
results were seen when celastrol was mixed with other
thiol- containing agents, such as NAC or GSH. Evidence
of reaction was not seen in celastrol and non-thiol small
molecules (Vit C or GSSG) mixtures (data not shown).
Interestingly, after adding an amount of formic acid (FA)
to the celastrol and DTT combination, celastrol's orange-
red color reappeared and mass spectrum analysis showed
m/z 451.25 (Figure 6D). This reading is consistent with
calculated mass of celastrol plus one hydrogen ion, and
thus indicates that the adduct reactions between celastrol
and thiol-containing agents are reversible under acidic
conditions. 1H NMR analysis further indicated that H6 in
celastrol's ring B might be the location for reactions (see
additional file 3).
Discussion
In this study, we investigated the effects and relevant
mechanisms of celastrol on human monocytic leukemia
cell line U937 proliferation. Celastrol's proven effective-
ness in anti-tumor treatments is thought to be primarily
due to apoptosis induction [12-15,23,24]. However, we
disclosed that in addition to causing cell death, this agent
could also arrest the cell cycle at G0/G1. This novel
action was accompanied by and related to down-regula-
tion of Cyclin D1 and its partners Cdk4, Cdk6, and Cdk2.
The interaction between Cyclin D1 and its partners,
especially Cdk4, is vital during the G1 phase, and disrup-
tion of either Cyclin D1 or Cdk4 can induce G0/G1 arrest
[25-27].
Cdk4, Cdk6, and Cdk2 are clients of HSP90 (see the
website http://www.picard.ch for details), and are
reported as being reduced by HSP90 inhibitors [17,18].
We thought the reductions of these Cdks in our model
might also be related to inhibition of HSP90, a recently
identified effect that celastrol has on different cell linesPeng et al. Molecular Cancer 2010, 9:79
http://www.molecular-cancer.com/content/9/1/79
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[11,12,21]. To support this line of thought, down-regula-
tion of these Cdks of our model was accompanied by
strong expression of HSP70, a telltale sign of HSP90 inhi-
bition. HSP90 inhibition was also confirmed by celastrol's
reduction of ATPase activities in the HSP90 immunopre-
cipitated complex, a finding that agrees with the latest
report [28]. Further supporting our hypothesis, co-
immunoprecipitation showed reductions in Cdk4 or
Cdk6 to HSP90 combinations. These findings are consis-
tent with previous reports describing celastrol's effective
disruption of HSP90-client-protein interactions and
down-regulation of HSP90 clients such as androgen
Figure 4 Effects of celastrol on HSP90's ATPase activity, HSP70 expression and the HSP90-Cdc37-Cdks complex. A: Celastrol inhibits the ac-
tivity of ATPase. Co-immunoprecipition of HSP90 was performed on untreated cells, and the beads-bound immunoprecipites were separated into 
three equal portions before incubation with celastrol, 17-AAG, or DMSO. ATPase activity was determined as the decrease of the absorbance at 340 
nm, detailed in Methods. B: Celastrol induces the increase of HSP70. Cells treated with 600 nM celastrol for 1 d and HSP70 levels were deteceted by 
flow cytometry, as detailed in Methods. X-axis shows channel number and Y-axis shows cell number. C: Celastrol disrupts the HSP90/Cdc37/Cdks com-
plexes. Cells treated with 600 nM celastrol for 1 d, then were used for immunoprecipitation by anti-HSP90 (H9010), detailed as in Methods. The left 
column (input) displays the detection based on total proteins of cells, while the right column (IP) shows detection of immunoprecipitation using the 
anti-HSP90 (H9010) antibody.
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Figure 5 Reversing effects of thiol-containing agents on the actions of celastrol in U937. Cells were seeded at 2 × 105/ml in a 24-well plate. After 
being pre-treated with 2 mM NAC, 0.1 mM Vit C, 2 mM GSH or 2 mM GSSG for 1 h, cells were exposed to 600 nM celastrol for 1 d. At the end of the 
indicated time points, cells were analysed for cell cycle location and protein detection by FCM. A: Flow cytometric histogram of HSP70 expressions in 
U937 with various treatments. B: Cell cycle distributions of drug treated U937. The dark gray, light gray and white areas in the circle track represent the 
ratio of cells at G0/G1, S, and G2/M phases, respectively. C: Expressions of selected proteins in U937 with different pre-treatments. The vertical axis 
represents the relative levels of each protein, which were determined by dividing individual protein intensity by its levels in the DMSO-treated sample. 
The DMSO-control sample was set at 1.0. The plotted data represents the mean results of three repetitions. The values under the figure are mean ± 
SD for each sample. * P < 0.05, **P < 0.01 when compared with DMSO-control.
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receptors (AR), Akt, epidermal growth factor receptors
(EGFR), etc [11,12,29]. It is worth noting that celastrol's
reduction of Cdk4 has also been observed in other cell
types [12], so it may be celastrol's general action to affect
this cell cycle regulator, a hypothesis that needs further
elucidation. Though Cyclin D1 is not a confirmed HSP90
client, its reduction could be explained as a result of
HSP90 inhibition. Cyclin D1 expression is controlled by
multiple signaling pathways, some key kinases of which
are affected by HSP90 [30-32]. Several of these kinases
have been proven to be affected by celastrol [24,29,33,34].
Nevertheless, direct interaction of celastrol and HSP90Peng et al. Molecular Cancer 2010, 9:79
http://www.molecular-cancer.com/content/9/1/79
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has not been demonstrated in vivo, and due to the reac-
tive nature of celastrol it is possible that it might have
additional targets which contribute to a stress response in
the cells.
Another of our important findings is that celastrol's
actions upon cell cycle and HSP90 clients can be reversed
by pre-treatment with thiol-containing agents, such as
NAC or GSH, but not by GSSG or non-thiol reducing
agents like Vit C. Our findings agree with previous inves-
tigations by Trott et al, who reported that celastrol
induced heat shock response- and antioxidant response-
inducible transcripts in RKO human colorectal carci-
noma cells, these effects decreasing upon incubation with
250 μM DTT [9]. These results, when viewed together,
indicate that thiol can reverse celastrol's actions.
To explore the possible mechanism for thiol-containing
agents' reversing effects toward celastrol, we investigated
the possibility of direct reaction between these agents
and celastrol. Free-thiol containing agents caused celas-
trol's colour to fade, while non-thiol agents did not give
Figure 6 Reactions between celastrol and thiol-containing agents and between celastrol and non-thiol small molecules. A: Absorption spec-
tra of celastrol mixed with different agents. Celastrol was mixed with different small molecules in ratio of 1:2, the absorption spectra then detected. B-
D: Mass spectrum analysis of the following agents or reactions: (B) celastrol; (C) the mixture of celastrol and DTT at a 1:2 molar ratio in DMSO; (D) cel-
astrol and DTT reaction result with formic acid added (to save space, the detection patterns presented have been truncated. The non-truncated view 
can be found in this manuscript's additional file 2).
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this primary evidence of direct reaction. Absorbance
spectrum analysis and MS detection provided further
evidence that celastrol was able to bind with thiol-con-
taining agents but not with non-thiol molecules. It has
been shown that celastrol can react or bind with some
proteins and truncated proteins [12,21,34], this combina-
tion achieved either by direct reactions of celastrol with
cysteine residues or by inserting celastrol into the 'pock-
ets' related to or affected by cysteine residues. Here we
f i n d  c o n v i n c i n g  e v i d e n c e  t h a t  c e l a s t r o l  d i r e c t l y  r e a c t s
with thiol. Since the thiol-containing agents we tested,
such as NAC and GSH, are small molecules and thus
non-'pocket' forming (as seen in the 3D structure of large
molecules), the bonds they form should be a direct chem-
ical reaction between celastrol and the thiol group. Our
results agree with the predication that the electrophilic
sites within celastrol's A and B rings could react with
nucleophilic groups of amino acid residues to form cova-
lent Michael adducts [35]. Sreeramulu et al recently
showed that H6 on celastrol's ring B might be the reactive
site [21], a finding further confirmed by our tests (see
additional file 3).
Therefore, the reversing effects of thiol-containing
agents might be achieved using either one or both of the
following ways. The first way is by bonding the thiol-con-
taining agents (we used) to celastrol to reduce pharmaco-
logical effect. Thiol modifications of this type are not rare
when reducing a drug's biological actions-- for example,
NAC reportedly forms a complex with geldanamycin to
reduce the latter's HSP90 inhibiting activities [36]. The
second way is that thiol-containing agents added to cells
compete with the cellular thiols targeted by celastrol, thus
lessening celastrol's overall impact on cellular thiols. Each
year in China, there are reports of death caused by the
toxicity of celastrol-containing preparations. The revers-
ing effects of thiol-containing agents indicated in these
models might be used for relief of such instances of celas-
trol-caused toxicity.
Direct thiol reaction also provided us with a new
understanding of celastrol-caused HSP90 inhibition. The
HSP90 chaperone complex consists of proteins that con-
tain the cysteine residues that are celastrol's potential tar-
gets. Of several cysteines in HSP90's middle and C-
terminals, at least one of them is important to HSP90
activity [37], and it cannot be ruled out that these are
attacked by celastrol. In fact, HSP90's C-terminal reac-
tion to celastrol was recently confirmed by Zhang et al.
[28]. (We also found preliminary evidence that celastrol
could directly reduce the number of reactive thiols in
recombinant human HSP90α in vitro). In addition to
HSP90 itself, cysteines in co-chaperones, especially
Cdc37, might be attacked by celastrol. Concurrent with
the preparation of this manuscript, Sreeramulu et al.
reported that celastrol could directly combine with
Cdc37 in a cysteine-dependent way [21]. Our results, like
previous reports [12], showed disruption of the HSP90/
Cdc37 complex, likely based on celastrol's effects upon
Cdc37. More generally, HSP90's clients and other regula-
tors of HSP90 with cysteines are all possible targets of
celastrol. In following with this consideration, the activi-
ties of HSP90's clients IKK, proteasome, and ERK were
directly inhibited when tested in a cell-free system
[15,29,34].
Celastrol's reaction with thiol also suggests that in addi-
tion to the HSP90 chaperone complex, other proteins
may be affected by celastrol. To support this supposition,
topoisomerase II, tubulin, and full-length mutant hun-
tingtin are all reported to directly react with celastrol in a
cell-free system [14,38,39]. The more proteins celastrol
affects, the greater the chance for side effects. It is reason-
able to consider that the spectrum of proteins targeted by
celastrol will become broader as dose increases. This is
because at low doses celastrol may only affect proteins
with rich content, but at high doses low-level proteins
may also be affected. Since HSP90 is one of the richest
proteins and has elevated expressions in tumor cells, we
would recommend low dosage application of this agent to
limit side effect risks.
Conclusions
We found that celastrol could arrest human monocytic
leukemia cells U937 at G0/G1 phase, this arrest accompa-
nied by down-regulation of Cyclin D1, Cdk4, Cdk6, and
Cdk2. This not only reveals a new action of celastrol, but
also suggests its possible application in leukemia and ath-
erosclerosis (a highly prevalent disease related to abnor-
mal monocyte proliferation) treatment. Direct reactions
between celastrol and thiol also shed new light on the
action of this HSP90 inhibitor providing a useful strategy
for relieving celastrol's toxicity. The target spectrum for
celastrol, however, might be dose-dependent. The answer
to such a question will ultimately need further investiga-
tion to provide a more detailed application basis for this
anti-proliferation agent.
Methods
Reagents and drugs
RPMI 1640 medium, fetal bovine serum (FBS) and strep-
tomycin/penicillin for cell culture were obtained from
PAA Laboratories (Linz, Austria). Propidium iodide (PI),
dimethyl sulfoxide (DMSO) and protease inhibitor cock-
t a i l  w e r e  p u r c h a s e d  f r o m  S i g m a  ( S t .  L o u i s ,  M O ) .  7 -
Amino-actinomycin D (7-AAD) was purchased from
Anaspec (San Jose, CA), carboxyfluorescein diacetate,
succinimidyle ester (CFSE) was purchased from Molecu-
lar Probe (Eugene, OR). 17-allylamino-17- demethoxy-
geldanamycin (17-AAG) was obtained from Invivogen
(San Diego, CA). N-acetylcysteine (NAC), reduced gluta-Peng et al. Molecular Cancer 2010, 9:79
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thione (GSH), oxidized glutathione (GSSG) and dithio-
threitol (DTT) were products of Amersco (Solon, OH).
ATP, NADH and pyruvate kinase (PK) were obtained
from BBI (distributed by Guan Yu Co., Shanghai, China).
Vitamin C (Vit C), L-lactate dehydrogenase (L-LDH) and
phosphoenolpyruvate (PEP) were obtained from Sigma
(St. Louis, MO). Protein A/G plus agarose was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
Cyclin D1 antibody was purchased from Zymed (South
San Francisco, CA). Anti-Cdk4 and Cdk2 antibodies were
purchased from BD Biosciences (San Jose, CA). Anti-
C dk 6 and C dc37 a n ti bodies w e r e  ob ta ined fr om  San ta
Cruz Biotechnology (Santa Cruz, CA). Anti-HSP70 was
purchased from USBiological (Swampscott, Massachu-
setts). Anti-HSP90 (H9010) for co-immunoprecipitation
was purchased from Alexis Biochemicals (San Diego,
CA), and anti-HSP90 (SPA-830) for western blot was
obtained from Stressgen Bioreagents (Ann Arbor, MI).
Anti-actin antibody, BCA protein assay reagent kit and
Beyo ECL Plus for western blot were purchased from
Beyotime Biotechnology (Jiangsu, China). All reagents
were stored as recommended by the manufactures.
Celastrol was extracted as previously reported by us
[33]. Celastrol was dissolved in 50 mM in DMSO and
stored at -20°C to be used within 3 months after prepara-
tion. The stored solution was further diluted with RPMI
1640 medium to a proper lower concentration immedi-
ately before experiments.
Cell culture and treatment
Human monocytic leukemia cell line U937 was obtained
from the Shanghai Cell Bank of the National Science
Academy of China (Shanghai). Cells were maintained in
RPMI 1640 supplemented with 10% FBS, 100 IU/ml peni-
cillin and 100 μg/ml streptomycin in a humidified 5%
CO2 incubator at 37°C. Exponentially growing cells were
used for experiments. Cells were seeded into 96-well or
24-well culture plates or 100 mm culture dishes at a den-
sity of 2 × 105/ml followed by exposure to indicated doses
of celastrol for an indicated time. The culture medium
with DMSO (vehicle) served as celastrol's control. The
final concentration of DMSO never exceeded 0.1%. Each
experiment was repeated at least three times.
Cell counting
At the end of indicated time points, cells were collected
and the living and dead cells enumerated. Accurate enu-
meration of living and dead cells was carried out by FCM
based on a single-tube platform with self-made cell-
Beads as internal controls, a method originally reported
by Harrison et al [19] and modified by us [20]. Briefly,
after samples were washed with PBS, a known number of
green fluorescence-containing Cell-Beads were added.
Before analysis by FACScalibur flow cytometer (Becton-
Dickinson, CA), PI with a final concentration of 1 μg/ml
was added. The FL1 flow cytometric detector was used
for discrimination between Cell-Beads and U937 cells,
based on the signal of green fluorescence which was posi-
tive for Cell-Beads but not for U937. The FL2 detector
was used to discriminate the living cells from the dead,
which tested negative and positive for PI's signal respec-
tively. The total events detected were 10,000. The number
of living (or dead) U937 cells was calculated using the fol-
lowing equation:
The Cell-Beads in our experiments were created by
labeling THP-1 cells with CFSE according to the manu-
facturer's recommended protocol. CFSE-labeled cells
were fixed with 1% paraformaldehyde and washed with
PBS. CFSE-labeled cells were stored at 4°C.
Cell cycle analysis
Following cold PBS wash, cells were fixed in 70% ice-cold
ethanol for 1 h. The samples were incubated in 50 μg/ml
RNase A and 25 μg/ml PI for 30 min at 37°C. The DNA
contents of more than 15,000 cells were detected by
FCM. Quantitative analysis of cell cycle distribution was
performed using ModFit LT Macintosh software (Verity
Software House, Inc., ME).
Apoptosis detection
Apoptotic cells were assessed using Annexin V- fluores-
cein isothiocynate (FITC) and PI double staining kit
(Jingmei biotechnology, China) according to the manu-
facturer's instructions. Briefly, after being washed twice
with cold PBS, Cells were incubated in 100 μl binding
buffer containing 5 μl Annexin V-FITC and 10 μl PI (20
μg/ml) for 15 min at room temperature in the dark.
Apoptotic cells were analysed by FCM.
Flow cytometric detection of protein expression
Following being washed with PBS, cells were fixed in
100% methanol for 10 min at 4°C, and then incubated in
the indicated primary antibodies for 45 min at 4°C, with
appropriate isotypes as control, following by the corre-
sponding secondary antibodies in conjunction with PE or
FITC for 30 min at 4°C. The samples were analyzed by
FCM. The analyses were performed with CellQuest soft-
ware (BD Biosciences). For samples that required for
simultaneous detection of proteins and cell cycle, cells
were subjected to RNA degradation (as mentioned
above) and DNA staining with 7-AAD after the second-
ary antibody labeling.
Co-immunoprecipitation and western blot
Cells were incubated in lysis buffer (20 mM Tris·HCl, 25
mM NaCl, 0.1% NP40, 2 mM DTT, 20 mM Na2MoO4,
Number of living  dead  U number of living  dead  U () [ () 937 937 = / /) ] number of Cell-Beads detected number of Cell-Beads inp × u utPeng et al. Molecular Cancer 2010, 9:79
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and protease inhibitor cocktail, pH 7.4) for 2 h at 4°C, and
lysates were cleared by centrifugation at 13,000 × g for 10
min. Protein concentrations were determined by BCA
protein assay reagent kit. 1 mg of proteins were incubated
with 2 μg of anti-HSP90 (H9010) antibody overnight at
4°C, and then 30 μl Protein A/G plus agarose was added
for additional 3 h at 4°C. Beads were washed three times
with PBS and diluted in 5 × SDS-sample buffer and
heated to 95°C for 5 min.
Aliquots of samples were loaded onto 10% SDS-poly-
acrylamide gels and then transferred to polyvinylidene
difluoride (PVDF) membranes. Membranes were probed
with indicated antibodies. Detection was accomplished
using corresponding horseradish peroxidase (HRP)-con-
jugated secondary antibodies followed by development
with Beyo ECL Plus and autoradiography with film.
ATPase activity assay
Untreated cells were co-immunoprecipitated using anti-
HSP90 (H9010) antibody as described above. Beads
bound to the immunoprecipites were washed and sepa-
rated into three equals portions. Each portion of beads
was then combined with either 0.06 mM of celastrol, 0.6
mM of 17-AAG, or 0.6 mM of DMSO at 37°C for 10 min.
The ATPase activity assay is based on a regenerating cou-
pled enzyme assay [22], in which the phosphorylation of
ADP during the catalyzation of phosphoenolpyruvate
(PEP) by pyruvate kinase (PK) is coupled to the reduction
of the resulting pyruvate by lactate dehydrogenase (LDH)
at the expense of NADH. Oxidation of NADH to NAD+
produced an absorbance decrease at 340 nm. Each 250 μl
assay contained 100 mM Tris-HCl (pH 7.4), 20 mM KCl,
6 mM MgCl2, 0.8 mM ATP, 0.1 mM NADH, 2 mM PEP,
0.2 mg PK, and 0.05 mg L-LDH. Following incubation,
drug-treated beads were added into the reaction buffer.
ATPase activity was detected as decreasing in absorbance
at 340 nm.
Reaction between celastrol and free-thiol containing 
agents in vitro
NAC, GSH, GSSG, DTT, or Vit C was added into 1 ml of
celastrol at 280 mM with a molecular ratio of 2:1, respec-
tively. The mixtures were then left at room temperature
for 30 min. The absorption spectra of the mixtures were
measured with an ultraviolet visible spectrophotometer
(UV757CRT, Shanghai Precision and Scientific Instru-
ment Co., Shanghai). The spectrums of celastrol alone
and of each reactant added alone were measured as con-
trol. To further study the reaction between celastrol and
thiol (non-thiol)-containing agents, celastrol was mixed
with these agents in a molar ratio of 1:2, respectively, in
DMSO for at least 20 min. The samples were analyzed by
Q-Tof micro YA019 mass spectrometer (Waters Corp.
USA).
Statistical analysis
Data are presented as mean ± SD. One-way analysis of
variance (ANOVA) was used for statistical evaluation of
significant differences among the groups using SPSS 11.5
for Windows software. A value of P < 0.05 was considered
to be statistical significance. Experiments were repeated
at least three times.
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